

MediKredit NAPPI Changes and Information

Circular Number: N027/2019
Circular Date: 18 October 2019
Effective Date: 17 October 2019

Important Notice

VOLUNTARY WITHDRAWAL OF PRODUCTS: (Zantac)

Please note that GlaxoSmithKline (GSK) and Aspen Pharmacare in agreement with the South African Health Products Regulatory Authority (SAHPRA) issued a recall of all batches of the Zantac range of products as per the table below:

NAPPI CODE	PRODUCT (Including Strength & Dosage Form)
703241	Zantac effervescent 75 mg EFT
778958	Zantac 150 mg TAB
778966	Zantac 2ml 50 mg INJ
778974	Zantac 300 mg TAB
788457	Zantac 150 mg per 10 ml SYR
791733	Zantac effervescent 300 mg EFT
811882	Zantac effervescent 150 mg TAB
822817	Zantac 75 mg TAB

NAPPI codes for these products have been discontinued and are not claimable.
Providers should immediately return all affected batches to their supply wholesaler/distributor for full credit.

For any further information and information on stock withdrawal please contact Aspen Customer Careline on 0800122912

Please note that Zantac has been loaded as exclusion on all MediKredit options and that patient authorizations for specific schemes are being terminated. Please refer your patients to their practitioners.

MediKredit Integrated Healthcare Solutions (Pty) Ltd

Head Office:
Johannesburg
10 Kikuyu Road, Sunninghill,
Sandton, 2157
P.O. Box 521058, Saxonwold, 2132



Johannesburg
Tel: Telkom: +27 (0) 11 770-6000
Call Centre: +27 (0) 860-932-273

www.medikredit.co.za